Target
$184.30 → $177.79
Current stock research snapshot · 7/8/26 49 days old
DGXQuest Diagnostics
Investment conviction●●○○○2 of 5 · current snapshot
Research target$177.79Current stock price target
Investment thesis statusINTACTLast reviewed 7/8/26
Market cap$25.22BSnapshot value · 7/8/26
Research history
See all DGX changes ↗What changed
Target
$184.31 → $184.30
National diagnostic lab network + screening access. Recurring test-volume revenue. Consumer-initiated testing expansion.
Consumer-initiated testing growth; screening guideline expansion (cancer, cardiovascular); value-based care partnerships.
Reimbursement rate pressure; labor cost inflation; competitive pressure from Labcorp and new entrants; PAMA (Protecting Access to Medicare Act) rate cuts.
Bullish — New all-time high in S&P 500 on Aug 26 2026 [X search Aug 2026]
Snapshot · 7/8/26🟡 Mixed · ins-$3.9M · 13F 13+/12-×0.5 · short↑0.33
Snapshot · 7/8/26Timestamped research update
Deep research update
388 words · Updated Jul 25, 2026 · 4 sources
Research in development: this latest 388-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Quest Diagnostics is a national diagnostic information-services company. It runs clinical labs, hospital reference testing, collaborative lab solutions, patient service centers, mobile phlebotomy, and consumer-facing access through MyQuest and QuestHealth.com.
FY2025 revenue was $11.035B, up 11.78% from FY2024; FY2025 gross margin was 33.21%, operating margin 14.10%, and net margin 8.99%. Q2 2026 revenue was $3.043B, up 10.2% YoY, with 15.08% operating margin; management raised full-year 2026 revenue guidance to $11.95B-$12.05B.
Quest monetizes access to the diagnostic workflow: ordering, specimen collection, reference testing, and lab operations. Its moat is not a single assay but the national distribution and workflow layer that hospitals, physicians, and consumers plug into.
- The FY2025 10-K says Quest serves approximately half the hospitals in the U.S. each year; in 2025 it generated about $1.2B from reference testing and about $800M from Collaborative Lab Solutions, or $2.0B in hospital-linked revenue, equal to 18.12% of FY2025 revenue.
- The July 23, 2026 EX-99.1 says Q2 2026 revenues were $3.04B, up 10.2% from 2025, with 10.0% organic revenue growth; operating income was $459M and the company raised full-year 2026 revenue guidance to $11.95B-$12.05B.
- The same release highlights continued Co-Lab Solutions implementation with Corewell Health, collaboration with Fresenius Medical Care, New York State approval for Haystack MRD, and the launch of IntelliDraw to improve specimen collection.
- The 10-K says Quest operates through laboratories, patient service centers, offices and other facilities around the U.S., and is expanding digital access via MyQuest and QuestHealth.com.
The moat is network density plus workflow lock-in: once a hospital outsources reference testing and lab operations, switching means revalidating assays, retraining staff, reworking logistics, payer/billing flows, and IT integrations. The hospital channel alone is $2.0B, so the switching surface is economically large.
- The business is still tied to reimbursement and volume mix; if price per requisition continues to compress faster than volume grows, margins can slip.
- Advanced diagnostics and consumer channels are growing, but they still need to prove they can offset cyclical or competitive pressure in core routine testing.
- How much of the $2.0B hospital-related revenue is contractually sticky versus exposed to insourcing, payer pressure, or competitive rebids?
- Does Haystack MRD and the broader advanced-diagnostics push materially shift mix in 2026-2027, or is it still small relative to routine testing?
STRENGTHENED
Primary and supporting material
Sources
4 sources preserved from the latest qualified research update.